Disease Landscape and Forecast Insights

The therapeutic landscape for recurrent or metastatic SCCHN has benefited from the introduction of only one novel treatment in the past several years, Erbitux in 2011. Although Erbitux has improved…

Introduction:The prevalence of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in Brazil and Mexico is estimated at 1.3 million and is expected to keep growing. The entry of biosimilars…

    Pharma’s interest in treatments for rare diseases has continued to intensify as the orphan sector sees rapid growth and attractive profit margins. Developers of orphan drugs can…

Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-…

Although there are several targeted agents approved for the treatment of metastatic renal cell carcinoma, including the approval of Opdivo by the FDA in November 2015, improvements in survival…

Five years after approval by the FDA and EMA, IV Benlysta remains the only drug licensed for the treatment of SLE in almost 60 years, highlighting the difficulty in successfully bringing to market…

Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At…

Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK…

Introduction Rheumatoid arthritis (RA) is a chronic disease that affects more than 1 million Brazilians and often requires the use of premium-priced therapies. The coverage of these drugs is…

Beta thalassemia is a recessive monogenic blood disorder characterized by low levels or an absence of the protein ß-globin, a key component of the oxygen transporting protein hemoglobin. A lack of…

Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy…

  Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial potential. Significant…